P30 CA16056/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
1994	1
1998	3
1999	15
2000	1
2001	9
2002	10
2003	21
2004	17
2005	18
2006	15
2007	13
2008	3
2009	2
2010	1
2011	2
2012	1
2013	1
2014	2
2015	2
2016	1
2020	2
2022	1
2024	0

1

Tumor microvasculature as a barrier to antitumor immunity.

Chen Q, Wang WC, Evans SS. Chen Q, et al. Cancer Immunol Immunother. 2003 Nov;52(11):670-9. doi: 10.1007/s00262-003-0425-4. Epub 2003 Aug 15. Cancer Immunol Immunother. 2003. PMID: 12920482 Review. No abstract available.

2

Dicer in immune cell development and function.

Devasthanam AS, Tomasi TB. Devasthanam AS, et al. Immunol Invest. 2014;43(2):182-95. doi: 10.3109/08820139.2013.863557. Epub 2013 Dec 4. Immunol Invest. 2014. PMID: 24303839 Free PMC article. Review.

3

HLA-G and MIC expression in tumors and their role in anti-tumor immunity.

Seliger B, Abken H, Ferrone S. Seliger B, et al. Trends Immunol. 2003 Feb;24(2):82-7. doi: 10.1016/s1471-4906(02)00039-x. Trends Immunol. 2003. PMID: 12547505 Review.

4

Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms.

Chang CC, Murphy SP, Ferrone S. Chang CC, et al. Hum Immunol. 2003 Nov;64(11):1057-63. doi: 10.1016/j.humimm.2003.08.357. Hum Immunol. 2003. PMID: 14602236 Review.

5

Heat shock proteins HSP70 and GP96: structural insights.

Facciponte JG, Wang XY, MacDonald IJ, Park JE, Arnouk H, Grimm MJ, Li Y, Kim H, Manjili MH, Easton DP, Subjeck JR. Facciponte JG, et al. Cancer Immunol Immunother. 2006 Mar;55(3):339-46. doi: 10.1007/s00262-005-0020-y. Epub 2005 Jul 20. Cancer Immunol Immunother. 2006. PMID: 16032399 Review.

6

Origin licensing and programmed cell death: a hypothesis.

Burhans WC, Blanchard F, Baumann H. Burhans WC, et al. Cell Death Differ. 2002 Sep;9(9):870-2. doi: 10.1038/sj.cdd.4401086. Cell Death Differ. 2002. PMID: 12181737 Review. No abstract available.

7

RRM1-induced metastasis suppression through PTEN-regulated pathways.

Gautam A, Li ZR, Bepler G. Gautam A, et al. Oncogene. 2003 Apr 10;22(14):2135-42. doi: 10.1038/sj.onc.1206232. Oncogene. 2003. PMID: 12687015

8

HLA class I defects in malignant lesions: what have we learned?

Chang CC, Campoli M, Ferrone S. Chang CC, et al. Keio J Med. 2003 Dec;52(4):220-9. doi: 10.2302/kjm.52.220. Keio J Med. 2003. PMID: 14748474 Free article. Review.

9

Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions.

Chang CC, Campoli M, Ferrone S. Chang CC, et al. Adv Cancer Res. 2005;93:189-234. doi: 10.1016/S0065-230X(05)93006-6. Adv Cancer Res. 2005. PMID: 15797448 Review.

10

Pan-Cancer Characterization of Intratumoral Autonomic Innervation in 32 Cancer Types in the Cancer Genome Atlas.

Zhang JF, Sheng H, Chen J, Mohammadpour H, Ma SJ, Farrugia MK, Gandhi S, Bouchard EG, Singh AK, Repasky EA, Khoury T, Ambrosone CB, Yao S. Zhang JF, et al. Cancers (Basel). 2022 May 21;14(10):2541. doi: 10.3390/cancers14102541. Cancers (Basel). 2022. PMID: 35626144 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

127 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year